YOLFTbeta
Rallybio Corp

Rallybio Corp

RLYB · NASDAQ · Healthcare / Biotechnology

15.72USD+0.07 (+0.45%)

Price History

Full chart

Market Stats

Previous Close15.65
Open15.62
Day Range15.50 – 15.79
52-Week Range3.67 – 17.57
Volume10.93K
Market Cap88.30M
P/E (TTM)2.08
Forward P/E0.00
EPS7.99
Dividend Yield0.00%
Beta-0.85
50-Day Avg16.64
200-Day Avg11.52

About

Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Stephen Uden M.D., MBBS
  • Employees7
  • Headquarters234 Church Street, New Haven, CT, United States, 06510, USA
  • Websitehttps://www.rallybio.com

Leadership

  • Dr. Martin W. MacKay Ph.D.Co-Founder & Chairman · b. 1956
  • Dr. Stephen Uden M.D., MBBSCo-Founder, President, CEO & Director · b. 1958

Financials

Income Statement

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00000636.00K858.00K
Growth (%)------+34.91%
Cost of Revenue26.34K62.03K109.00K167.00K150.00K39.51M92.00K
Gross Profit-26.34K-62.03K-109.00K-167.00K-150.00K-38.87M766.00K
Gross Margin------6111.79%89.28%
Operating Expense17.62M25.24M45.54M67.72M78.78M21.63M28.83M
Operating Income-17.64M-25.30M-45.65M-67.88M-78.93M-60.50M-28.06M
Operating Margin------9511.95%-3270.86%
EBITDA-17.39M-25.24M-45.39M-67.72M-78.78M-60.37M-27.97M
EBITDA Margin------9491.35%-3260.14%
Net Income-17.63M-26.45M-47.01M-66.65M-74.56M-57.77M-8.98M
Net Income Margin------9084.12%-1046.39%
R&D11.37M17.63M26.91M40.69M53.54M41.51M19.60M
R&D as % of Total Revenue-----6526.26%2284.03%
Interest Expense39.00K49.00K10.00K2.31M---

Balance Sheet

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets21.61M141.86M182.19M180.44M115.62M68.11M62.26M
Total Liabilities4.75M5.86M6.58M11.12M9.44M6.45M4.30M
Total Equity16.86M136.00M175.60M169.32M106.18M61.65M57.96M
Cash19.46M140.23M175.33M56.96M24.49M13.90M31.37M
Total Debt---555.00K392.00K154.00K176.00K
Net Debt-19.46M-140.23M-175.33M-56.40M-24.10M-13.75M-31.20M

Cash Flow

Currency: USD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-15.03M-22.04M-45.53M-57.28M-60.27M-49.28M-29.81M
Investing Cash Flow-188.00K-2.07M-2.33M-112.17M27.66M33.49M47.27M
Financing Cash Flow31.57M144.89M82.97M51.08M143.00K5.20M16.00K
Capital Expenditure188.00K137.00K333.00K54.00K12.00K00
Free Cash Flow-15.21M-22.18M-45.87M-57.34M-60.28M-49.28M-29.81M
FCF to OCF101.25%100.62%100.73%100.09%100.02%100.00%100.00%

Earnings

Report DateMar 31, 2020Mar 31, 2021Jun 2, 2021Sep 9, 2021Nov 10, 2021Mar 15, 2022May 10, 2022Aug 8, 2022Nov 7, 2022Mar 6, 2023May 9, 2023Aug 8, 2023Nov 9, 2023Mar 12, 2024May 9, 2024Aug 8, 2024Nov 7, 2024Mar 13, 2025May 8, 2025Aug 7, 2025Nov 6, 2025Mar 17, 2026May 13, 2026Aug 6, 2026Nov 5, 2026
EPS Estimate0.000.000.00-2.80-7.08-0.39-3.76-4.88-4.32-0.60-3.72-3.77-3.98-0.45-3.68-2.86-2.70-0.30-2.28-1.96-1.56-0.15-1.20-1.28-
EPS Actual-1.97-4.11-4.11-2.80-2.96-0.42-3.84-4.56-4.80-0.46-3.44-3.68-3.60-0.50-3.76-2.96-2.080.25-1.68-0.222.88-1.52-1.46-1.09-
Surprise---0.00%58.19%-7.69%-2.13%6.56%-11.11%23.33%7.53%2.39%9.55%-11.11%-2.17%-3.50%22.96%183.33%26.32%88.78%284.62%-891.52%-21.67%14.84%-
Timing---After-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market-After-hoursPre-market-

Key Statistics & Ratios

Market Cap88.30M
Enterprise Value-3.28M
Trailing P/E2.08
Forward P/E0.00
Price / Sales136.68
Price / Book0.95
EPS7.99
Book Value17.81
Revenue (TTM)646.00K
Gross Profit (TTM)-9.18M
EBITDA-25.38M
Profit Margin7051.24%
Operating Margin-3935.45%
Return on Equity64.86%
Return on Assets-21.32%
Shares Outstanding5.31M
Shares Float1.76M
Beta-0.85
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 4 analystsTarget 8.00
  • Strong Buy
    1
  • Hold
    3

Ownership Breakdown

Institutions
86.13%
Insiders
24.27%
Retail / Other
0.00%

Top Institutional Holders

  • FMR Inc
    793.45K14.94%
  • Viking Global Investors LP
    524.35K9.87%
  • Cormorant Asset Management, LLC
    400.00K7.53%
  • TPG GP A, LLC
    378.55K7.13%
  • Balyasny Asset Management LLC
    376.57K7.09%
  • LAURION CAPITAL MANAGEMENT LP
    302.76K5.70%
  • Nantahala Capital Management, LLC
    300.63K5.66%
  • Pivotal bioVenture Partners Investment Advisor LLC
    300.58K5.66%
  • Almitas Capital LLC
    191.21K3.60%
  • Renaissance Technologies Corp
    156.53K2.95%
  • Vanguard Capital Management, LLC
    112.04K2.11%
  • AJU IB Investment Co Ltd
    94.33K1.78%
  • Citadel Advisors Llc
    72.20K1.36%
  • Mariner Wealth Advisors LLC
    50.57K0.95%
  • Geode Capital Management, LLC
    35.42K0.67%
  • ADAR1 Capital Management LLC
    20.54K0.39%

Top Fund Holders

  • Fidelity Growth Company Fund
    207.41K3.93%
  • Vanguard MStar Total Stk Mkt Idx Invest
    134.62K2.55%
  • Fidelity Growth Company K6
    56.78K1.07%
  • Fidelity Series Growth Company
    53.60K1.01%

Dividends

20261×
13.56Nov 6, 2026

Stock Splits

  • Feb 6, 20261:8